NCT00054899已完成1 期
An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)
Epimmune16 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2003年1月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 16
研究概览
简要总结
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Non-Small Cell Lung Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa
- •At least four weeks following prior standard treatment, with no evidence of disease
- •Must use adequate birth control
排除标准
- •Prior cancer vaccine therapy or concurrent participation in any other investigational study
- •A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment
- •A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine
- •Women who are pregnant, intend to become pregnant, or who are breast feeding
研究者
研究点 (16)
Loading locations...
相似试验
已完成
1 期
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon CancerColonic NeoplasmsColorectal NeoplasmsNCT00054912Epimmune18
Unknown
2 期
Phase II Study of S-488410 to Treat Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT01592617Shiga University45
终止
1 期
VAccination in Early and ADvanced Prostate caNCErIntermediate Risk Prostate CancerCastration-resistant Prostate CancerNCT03815942University of Oxford23
撤回
2 期
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01741038Mirror Biologics, Inc.
已完成
1 期
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic CancerNon-Small-Cell Lung CarcinomaPancreatic CancerRenal Cell CarcinomaNCT00056537Active Biotech AB44